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Abstract: BACKGROUND Carcinoma of unknown primary origin (CUP) accounts for 2%-5% of newly
diagnosed advanced malignancies, with chemotherapy as the standard of care. CUPISCO (NCT03498521)
is an ongoing randomized trial using comprehensive genomic profiling (CGP) to assign patients with CUP
to targeted or immunotherapy treatment arms based on genomic profiling. We performed a retrospective
analysis of CUP cases referred for CGP to determine how many were potentially eligible for enrollment
into an experimental CUPISCO arm. MATERIALS AND METHODS Centrally reviewed adenocar-
cinoma and undifferentiated CUP specimens in the FoundationCore database were analyzed using the
hybrid capture-based FoundationOne CDx assay (mean coverage, >600×). Presence of genomic alter-
ations, microsatellite instability (MSI), tumor mutational burden (TMB), genomic loss of heterozygosity
(gLOH), and programmed death-ligand 1 (PD-L1) positivity were determined. RESULTS A total of 96 of
303 patients (31.7%) could be matched to an experimental CUPISCO arm. Key genomic alterations in-
cluded ERBB2 (7.3%), PIK3CA (6.3%), NF1 (5.6%), NF2 (4.6%), BRAF (4.3%), IDH1 (3.3%), PTEN,
FGFR2, EGFR (3.6% each), MET (4.3%), CDK6 (3.0%), FBXW7, CDK4 (2.3% each), IDH2, RET,
ROS1, NTRK (1.0% each), and ALK (0.7%). Median TMB was 3.75 mutations per megabyte of DNA;
34 patients (11.6%) had a TMB greater or equal to 16 mutations per megabyte. Three patients (1%)
had high MSI, and 42 (14%) displayed high PD-L1 expression (tumor proportion score ฀50%). gLOH
could be assessed in 199 or 303 specimens; 19.6% had a score of >16%. CONCLUSIONS Thirty-two
percent of patients would have been eligible for targeted therapy in CUPISCO. Future studies, including
additional biomarkers such as PD-L1 positivity and gLOH, may identify a greater proportion poten-
tially benefiting from CGP-informed treatment. Clinical trial identification number. NCT03498521
IMPLICATIONS FOR PRACTICE: The findings of this retrospective analysis of carcinoma of unknown
primary origin (CUP) cases validate the experimental treatment arms being used in the CUPISCO study
(NCT03498521), an ongoing randomized trial using comprehensive genomic profiling to assign patients
with CUP to targeted or immunotherapy treatment arms based on the presence of pathogenic genomic
alterations. The findings also suggest that future studies including additional biomarkers and treatment
arms, like programmed death-ligand 1 positivity and genomic loss of heterozygosity, may identify a greater
proportion of patients with CUP potentially benefiting from comprehensive genomic profiling-informed
treatment.
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ABSTRACT
Background. Carcinoma of unknown primary origin (CUP)
accounts for 2%–5% of newly diagnosed advanced malig-
nancies, with chemotherapy as the standard of care.
CUPISCO (NCT03498521) is an ongoing randomized trial
using comprehensive genomic profiling (CGP) to assign
patients with CUP to targeted or immunotherapy treatment
arms based on genomic profiling. We performed a retro-
spective analysis of CUP cases referred for CGP to deter-
mine how many were potentially eligible for enrollment
into an experimental CUPISCO arm.
Materials and Methods. Centrally reviewed adenocarci-
noma and undifferentiated CUP specimens in the
FoundationCore database were analyzed using the hybrid
capture-based FoundationOne CDx assay (mean coverage,
>600×). Presence of genomic alterations, microsatellite
instability (MSI), tumor mutational burden (TMB), genomic
loss of heterozygosity (gLOH), and programmed death-
ligand 1 (PD-L1) positivity were determined.
Results. A total of 96 of 303 patients (31.7%) could be mat-
ched to an experimental CUPISCO arm. Key genomic alter-
ations included ERBB2 (7.3%), PIK3CA (6.3%), NF1 (5.6%),
NF2 (4.6%), BRAF (4.3%), IDH1 (3.3%), PTEN, FGFR2, EGFR
(3.6% each), MET (4.3%), CDK6 (3.0%), FBXW7, CDK4 (2.3%
each), IDH2, RET, ROS1, NTRK (1.0% each), and ALK (0.7%).
Median TMB was 3.75 mutations per megabyte of DNA;
34 patients (11.6%) had a TMB greater or equal to 16 muta-
tions per megabyte. Three patients (1%) had high MSI, and
42 (14%) displayed high PD-L1 expression (tumor propor-
tion score ≥50%). gLOH could be assessed in 199 or
303 specimens; 19.6% had a score of >16%.
Conclusions. Thirty-two percent of patients would have been
eligible for targeted therapy in CUPISCO. Future studies,
including additional biomarkers such as PD-L1 positivity and
gLOH, may identify a greater proportion potentially benefit-
ing from CGP-informed treatment. Clinical trial identification
number. NCT03498521 The Oncologist 2020;9999:• •
Implications for Practice: The findings of this retrospective analysis of carcinoma of unknown primary origin (CUP) cases
validate the experimental treatment arms being used in the CUPISCO study (NCT03498521), an ongoing randomized trial
using comprehensive genomic profiling to assign patients with CUP to targeted or immunotherapy treatment arms based
on the presence of pathogenic genomic alterations. The findings also suggest that future studies including additional bio-
markers and treatment arms, like programmed death-ligand 1 positivity and genomic loss of heterozygosity, may identify a
greater proportion of patients with CUP potentially benefiting from comprehensive genomic profiling-informed treatment.
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INTRODUCTION
“Carcinoma of unknown primary origin” (CUP) describes a
heterogeneous group of cancers determined to be meta-
static at diagnosis but for which a primary tumor cannot be
identified based on a full standardized diagnostic workup
[1]. They are surprisingly common, accounting for 2%–5%
of all malignancies, and are associated with extremely poor
survival of approximately 1 year or less [2, 3]. Standard
therapy for CUP has not changed for decades, a fact that
establishes the disease as an unmet medical need requiring
immediate attention.
Depending on the clinical constellation, histology, and
immunophenotype, CUP can be divided into two clinico-
pathologic subtypes: the more localized form with a favor-
able prognosis of 12–36 months, and the widely dissemi-
nated form with an unfavorable prognosis of less than
1 year [4]. However, only 10%–15% of patients compose
the favorable subset; the majority belong to the poor-risk
subset of patients who are treated with platinum-based
chemotherapy [4]. Comprehensive genomic profiling (CGP)
may reveal more personalized and effective therapeutic
options for these patients. Rather than conducting a poten-
tially futile diagnostic search for the primary tumor origin
through multiple investigations, including multimodality
diagnostic imaging procedures, tissue immunohistochemis-
try (IHC) panels, serum tumor marker panels, and messen-
ger RNA profiling [5], CGP aims to identify pathogenic
genomic alterations in patients with CUP regardless of the
primary tumor site [6]. Recent studies have shown a lack of
clinical benefit of site-specific chemotherapy or targeted
therapies directed by gene expression profiling to deter-
mine the tissue of origin (vs. chemotherapy) in patients
with CUP [7, 8]; in contrast, evidence for the validity of
CGP-informed therapy was bolstered by a study in 2015, in
which next-generation sequencing of tumoral DNA from
200 CUP specimens identified at least one clinically relevant
genetic aberration in 85% of cases [5]. Notably, one patient
with brain metastases harbored an amplification of the
MET gene and demonstrated a complete clinical response
to crizotinib [5]. The efficacy of CGP-informed therapy was
further suggested in the recent I-PREDICT trial; in patients
with refractory tumors, targeting a larger fraction of identi-
fied molecular alterations correlated with significantly
improved disease control rates and longer progression-free
(PFS) and overall survival (OS) rates [9].
CUPISCO is a phase II, randomized, multicenter study of
patients with newly diagnosed, unfavorable CUP
(NCT03498521) that will compare the efficacy and safety of
targeted therapy or cancer immunotherapy, guided by
genomic profiling, with platinum-based standard chemo-
therapy [10]. All enrolled patients will receive genomic pro-
filing from Foundation Medicine, Inc. on tissue or blood,
and, after three rounds of induction chemotherapy, patients
experiencing disease control (partial or complete response
or stable disease) will be randomized to either standard
chemotherapy continuation or experimental treatment of
molecularly guided therapies following assignment by a
molecular tumor board (Fig. 1). Patients not responding to
induction chemotherapy will also undergo molecular tumor
board–based treatment assignment for the same molecu-
larly guided therapies, but in a nonrandomized fashion and
without a comparator. Patients will be treated until loss of
clinical benefit and will be monitored for PFS (primary end-
point), OS, clinical benefit duration, and safety (secondary
endpoints). Results will provide insight into whether CGP-
informed therapies are superior to standard unspecific che-
motherapy in CUP [10].
The aim of the present study was to perform a retro-
spective analysis of CUP cases referred to CGP testing at a
Clinical Laboratory Improvement Amendments (CLIA)–certi-
fied, College of American Pathologists (CAP)–accredited lab-
oratory (Foundation Medicine, Inc.) to estimate how many
patients could be matched to one of nine experimental
CUPISCO arms based on the inclusion criteria used in
CUPISCO. In addition, we aimed to determine whether bio-
markers not currently included in CUPISCO, such as
programmed death-ligand 1 (PD-L1) status or genomic loss
of heterozygosity (gLOH), may provide additional clinical
value to CUPISCO and any related future trials. We also
examined whether additional mutations not currently used
for stratification in CUPISCO may increase the spectrum of
patients who can be treated with CGP-informed therapy.
MATERIALS AND METHODS
Tumor samples were composed of archival tissue from
303 consecutive centrally reviewed adenocarcinoma and
undifferentiated CUP cases in the FoundationCore data-
base. CUP was defined as a heterogeneous group of meta-
static tumors for which a standardized diagnostic workup
fails to identify the site of origin at the time of diagnosis.
Criteria to classify as CUP and method of review of patient
specimens can be found in the 2015 CUP European Society
for Medical Oncology guidelines [11]. Genomic profiling
was performed in a CLIA-certified, CAP-accredited labora-
tory (Foundation Medicine, Inc., Cambridge, MA) using the
Illumina HiSeq 4000 instrument (Illumina, Inc., San Diego,
CA) on the CDx, U.S. Food and Drug Administration (FDA)–
approved platform [12]. At least 50 ng of DNA per specimen
was isolated and sequenced to high, uniform coverage
(mean, >600×), as previously described [13]. The DNA
extracted from CUP formalin-fixed, paraffin-embedded
tumor specimens was analyzed after hybridization capture
of 324 cancer-related genes and introns from 34 genes
commonly rearranged in cancer. Genomic alterations
detected by this assay included base substitutions, inser-
tions and deletions (short variants), rearrangements, and
copy number changes. Microsatellite instability (MSI),
tumor mutational burden (TMB), and gLOH (defined as a
biomarker of homologous recombination deficiency and
response to poly-ADP ribose polymerase inhibitors [PARPi])
[14] were also calculated, as described previously [15–18].
Regarding TMB, patients were stratified into either
TMB-high (TMB ≥16 mutations per Mb [Mut/Mb]) or TMB-
low (TMB <16 Mut/Mb) based on cutoffs used in CUPISCO
to determine whether those of the TMB-low cohort, typi-
cally associated with a reduced response to immunotherapy
[19], could still be matched to a targeted treatment arm.
PD-L1 expression was measured by DAKO 22C3 IHC (Dako
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Denmark, Glostrup, Denmark) and reported as negative (0%
tumor cell staining), low positive (1%–49%), or high positive
(≥50%). Cases determined by IHC to be TTF-1+, CK7–/CK20
+/CDX2+, or TMPRSS2:ERG+ were excluded as such tumors
belong to a subgroup of CUP with favorable prognosis (lung,
colorectal, or prostate cancer). Overlap of biomarkers was
also analyzed (gLOH-high, TMB-high, PD-L1-high, MSI-high).
Figure 2 presents a summary of the experimental procedure.
Approval for this study, including a waiver of informed con-
sent and a Health Insurance Portability and Accountability
Act waiver of authorization, was obtained from the Western
Institutional Review Board (Protocol No. 20152817).
Sequence analysis methods and validation of the CGP
platform used in this study have been described previously
by Frampton and colleagues [13, 20]. Base substitution
detection was performed using the Bayesian methodology,
which enables the detection of novel somatic mutations at
low mutant allele frequency (MAF) and increased sensitivity
for mutations at hot-spot sites through the incorporation of
tissue-specific prior expectations [13]. Reads with mapping
quality less than 25 were discarded, as were base calls with
quality 2 or less. Final calls were made at MAF of at least
5% (MAF ≥1% at hot spots) to avoid false-positive calls [13],
after filtering for strand bias (Fisher test, p < .001), read
location bias (Kolmogorov–Smirnov test, p < .001), and
presence in two or more normal controls. To detect short
insertions or deletions (indels), de novo local assembly in
each targeted exon was performed using the De Bruijn
approach [13]. After read pairs were collected and
decomposed, the statistical support for competing haplo-
types was evaluated and candidate indels were aligned
against the reference genome. Filtering of indel candidates
was carried out as described for base substitutions [13].
Gene amplifications and homozygous deletions were
detected by comparing complete chromosomal copy num-
ber maps to reference process-matched, normal control
samples, and gene fusions and rearrangements were
detected by analysis of chimeric read pairs [13]. Trinucleo-
tide mutational signatures were generated based on tech-
niques described previously [21]. Analysis required the
presence of 20 point mutations (excluding pathogenic
mutations but including synonymous and noncoding alter-
ations); the mismatch repair signature included COSMIC sig-
nature 1 in addition to 6, 15, 20, and 26 [22].
Analysis of germline variants was limited to known or
likely variants (no variants of uncertain significance were
included). The investigational method for detection of
germline mutations, as described previously [23], was dem-
onstrated in 30 tumor samples with matched-normal as a
gold standard. In this data set, we observed a 99% accuracy
for germline calls (151 of 153 variant calls).
Statistical Analysis
Error bars on frequency represent the 95% binomial confi-
dence interval. Proportions were compared using the Fish-
er’s exact test. gLOH distributions were compared using the
nonparametric Mann-Whitney U test.
RESULTS
Three hundred and three patients were identified who
were referred for testing between 2018 and 2019:
96 (31.7%) matched to one of the experimental CUPISCO
trial arms (Table 1). The sex ratio was 1:1 (male, n = 151;
female, n = 152), and median patient age was 67 (range,
22–89+) years.
Overall, there were 220 of 324 genes in the
FoundationOne CDx bait set that were altered in at least
one of the 303 patients (Fig. 3). Key genomic alterations
included ERBB2 (7.3%), PIK3CA (6.3%), NF1 (5.6%), NF2
(4.6%), BRAF (4.3%), IDH1 (3.3%), PTEN (3.6%), FGFR2
(3.6%), EGFR (3.6%), MET (4.3%), CDK6 (3.0%), FBXW7
(2.3%), CDK4 (2.3%), IDH2 (1.0%), RET (1.0%), ROS1 (1.0%),
NTRK1 (1.0%), and ALK (0.7%). Of 11 FGFR2 genomic alter-
ations, 7 (63.6%) were gene fusions or rearrangements.
KRAS was mutated in 27.4% of specimens, and 6.3% had
G12C alterations.
Of the 303 samples, 294 had a TMB estimate. Median
TMB was 3.75 Mut/Mb of DNA; 23.1% (n = 68) of speci-
mens possessed ≥10 Mut/Mb. Thirty-four specimens
(11.6%) harbored ≥16 Mut/Mb of DNA, and 25 (8.5%) had
≥20 Mut/Mb.
Of the 34 cases with a high TMB, 23 were assessable for
a mutational signature. Fifteen had a dominant mutational
signature; eight (34.7%) had a tobacco, five (21.7%) had an
ultraviolet light, and two (8.7%) had a mismatch repair
mutational signature. Within the TMB-low data set, 252 of
260 (96.9%) specimens displayed pathogenic mutations,
with 20 genes altered in at least 5% of specimens; in con-
trast, within the TMB-high data set, all 34 specimens dis-
played pathogenic mutations, and 55 genes were altered in
at least 5% of specimens (Fig. 4). Out of the 260 TMB-low
cases, we observed 18 (6.9%) with ERBB2 amplifications,
15 (5.8%) with KRAS G12C alterations, 7 (2.7%) with FGFR2
rearrangements, and 5 (1.9%) with ERBB2-activating short
variants (Fig. 4). Across all cases, alterations in STK11,
KEAP1, and SMARCA4 occurred in 55 (18.2%), 25 (8.3%),
and 34 (11.2%) patients, respectively (Fig. 4); KEAP1 and
SMARCA4 alterations occurred more frequently in the TMB-
high subgroup (STK11: 6/34 [17.7%] vs. 49/260 [18.9%];
KEAP1: 6/34 [17.7%] vs. 19/260 [7.3%]; SMARCA4: 6/34
[17.7%] vs. 26/260 [10.0%]).
The present study also examined whether biomarker
analysis not currently included in CUPISCO (such as PD-L1
status, presence of germline mutations, or gLOH) could add
further clinical value to the trial.
PD-L1 immunostaining, a predictor of response to
immunotherapy, identified 42 cases (13.9%) that displayed
a high level of expression of PD-L1. Of the 303 specimens,
three (1.0%) were MSI-high. Analysis of putative cancer-
associated germline mutations in somatic tumor tissue was
limited to 264 samples, with 59 (22.4%) specimens harbor-
ing a predicted germline event.
gLOH could be assessed in 199 of 303 specimens,
39 (19.6%) of which had a high gLOH (gLOH >16). Strong
homologous recombination-associated genes, including
BRCA1/2 and PALB2, were mutated in 11 of 199 (5.5%)
cases, and weaker homologous recombination-associated
© 2020 AlphaMed Presswww.TheOncologist.com
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genes (RAD51B, RAD51D, BARD1, RAD51C, PPP2R2A, BRIP1,
FANCL, CDK12, CHEK1, ATM, CHEK2, and RAD54L) were
mutated in 18 (9.0%). Mutations in strong homologous
recombination-associated genes were associated with a
higher gLOH than homologous recombination wildtype
(55% vs. 16% had gLOH >16; 95% confidence interval [CI],
23.4–83.3; p = .03). Mutations in weak homologous
recombination-associated genes were also associated, but
not significantly, with a high gLOH (39% vs. 16% had gLOH
>16; 95% CI, 17.3–64.3; p = .06). Biallelic alterations were
more strongly associated with gLOH.
Analysis of overlap of biomarkers (gLOH-high, TMB-high,
PD-L1-high, MSI-high) was limited to cases in which the sta-
tus of all four biomarkers was known (n = 191); analysis
demonstrated little overlap (Fig. 5).
DISCUSSION
CUP is among the 10 most common cancers for men and
women worldwide [24]. Current treatment strategies, com-
posed of platinum-based chemotherapy, only control the
disease for a short period, with most patients surviving less
than 1 year after diagnosis [2–4, 8]. CUPISCO is a random-
ized phase II trial examining the efficacy and safety of CGP-
informed targeted therapy and immunotherapy in patients
with newly diagnosed CUP [10]. The present study does not
include data from CUPISCO itself but is instead a retrospec-
tive analysis of CUP cases using the same CGP assay to be
used in CUPISCO. The aim was to determine how many
cases would be potentially eligible for the targeted therapy
and immunotherapy arms of CUPISCO and to inform new
arms that could be added to the trial based on the emerg-
ing molecular insights. However, it should be noted that the
pending data from CUPISCO mean that all findings should
be treated with caution and require full validation once
CUPISCO commences.
In the study, specimens from 303 patients with unfavor-
able CUP were analyzed, with 96 (31.7%) being matched to
a CUPISCO arm, thus validating the experimental arms used
in the study [10]. Key genomic alterations included ERBB2,
PIK3CA, NF1, NF2, BRAF, PTEN, EGFR, CDK6, BRCA2, FBXW7,
BRCA1, CDK4, ROS1, RET, IDH2, ALK, PTCH1, and AKT1;
many of these alterations are potentially actionable with
targeted treatment. In that regard, previous studies have
shown that carcinomas driven by activating ERBB2 muta-
tions can respond to anti-ERBB2 therapies including
trastuzumab, lapatinib, and afatinib [25, 26]. Furthermore,
in a recent next-generation sequencing-based study of
patients with CUP, one patient harboring ERBB2 amplifica-
tion was treated with trastuzumab plus paclitaxel and con-
sequently demonstrated a sustained partial response at
9 months until data cutoff [27]. Regarding BRAF alterations,
a multicohort “basket” study of the BRAF inhibitor
vemurafenib in patients with nonmelanoma BRAFV600
mutation-positive solid tumors demonstrated clinical
responses in 13 unique cancer types, including historically
treatment-refractory tumors such as cholangiocarcinoma,
sarcoma, glioma, neuroendocrine carcinoma, and salivary
gland carcinoma [28]. These results suggest that even
single-agent BRAF inhibition may have therapeutic
relevance across many cancer types, including CUP [28],
although the exact therapeutic regimen may vary
depending on the cancer type (e.g., use of BRAF inhibitors
alone or in combination with other therapies in melanoma
and non-small cell lung cancer, respectively [29, 30]).
Interestingly, patients in the present study also dis-
played genetic changes in the IDH1, MET, and FGFR2 genes,
as well as KRAS G12C alterations. IDH1 mutations have
been found to occur frequently in cholangiocarcinoma
which is a putative primary site in many cases of CUP [31].
A phase III trial comparing the IDH1 inhibitor ivosidenib
with placebo in patients with advanced or metastatic
mutant IDH1 cholangiocarcinoma demonstrated a signifi-
cant improvement in median PFS and, when adjusted for
patients crossing from placebo to ivosidenib, OS (PFS, 2.7
vs. 1.4 months; hazard ratio, 0.37; 95% confidence interval
[CI], 0.25–0.54; p < .001; OS: 10.8 vs. 6.0 months; hazard
ratio, 0.46; p < .001) [32]. Furthermore, in the study by Ross
and colleagues in 2015, one patient with an abdominal
mass and solitary brain metastasis on imaging and a
16-copy amplification of the MET gene showed a complete
clinical benefit upon treatment with crizotinib [5]. In addi-
tion to this, based on positive efficacy results in the phase II
GEOMETRY mono-1 study [33], the highly potent and selec-
tive MET inhibitor capmatinib has been granted priority
review by the FDA for first-line and previously treated
patients with locally advanced or metastatic MET-mutated
non-small cell lung cancer (NSCLC) [34]. The FGFR2 inhibitor
pemigatinib has also recently been granted accelerated
approval for patients with previously untreated, locally
advanced or metastatic FGFR2-mutant cholangiocarcinoma,
and the KRAS G12C inhibitor AMG-510 is currently being
investigated in phase I/II trials of patients with advanced,
mutant solid tumors [35, 36]. As a consequence of results
here, pemigatinib and possibly ivosidenib will be included
as additional targeted therapies in CUPISCO, thus extending
the spectrum of patients who can be treated with CGP-
informed therapy.
The present study found the median TMB to be 3.75
Mut/Mb of DNA, with 11.6% of patient specimens
possessing 16 or more; numerous studies have found an
association of high TMB with clinical benefit from check-
point inhibitors [19]. Additionally, 97% of TMB-low speci-
mens still harbored pathogenic alterations and would
potentially remain eligible for targeted therapy, with nota-
ble examples including ERBB2 amplification, KRAS G12C
alterations, and FGFR2 rearrangements. Interestingly,
among TMB-high specimens, STK11 and KEAP1 were each
altered in 6 of 34 (17.7%). Given the recent findings demon-
strating that STK11/KEAP1 mutations reduce the clinical
benefit of PD-L1 inhibitors in patients with NSCLC [37, 38],
the detection of these alterations in our study may help to
inform the use of cancer immunotherapy. SMARCA4 vari-
ants also occurred in 6 of 34 (17.7%) patients, although
such alterations have been observed to be enriched in thy-
roid transcription factor-1 IHC-negative NSCLC [39],
suggesting that these specimens may represent NSCLC not
detected by the computed tomography scan.
In the present study, 19.6% of specimens had a gLOH
score of greater than 16% of the genome, a level that
© 2020 AlphaMed Press
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predicted benefit of the PARPi rucaparib in patients with
advanced high-grade epithelial ovarian cancer [17].
Although CUPISCO already includes a PARPi-based treat-
ment arm (olaparib), the high gLOH >16 percentage
reported here suggests that gLOH could be used addition-
ally for stratification into this arm. Furthermore, 14% of
specimens in the present study displayed a high level of
expression of PD-L1 (tumor proportion score ≥50%), a level
which has previously been associated with immunotherapy
responsiveness in lung cancer [40]. These findings suggest
that use of additional biomarkers such as gLOH and PD-L1
positivity in future studies may identify a greater proportion
of patients with CUP potentially benefiting from CGP-
informed treatment (up to 19% and 14%, respectively),
especially considering the little overlap of PD-L1 positivity
or gLOH with TMB-high. The findings also suggest that it
may be useful in future trials based on PD-L1 positivity or
gLOH to include an additional arm for patients with a diag-
nosis of CUP, rather than require all patients to be diag-
nosed with a tumor of specific primary origin.
The present study lacks detailed clinical data for each
specimen, including whether any patients received special-
ized therapy and subsequently demonstrated therapeutic
benefit. To date, large-scale evidence illustrating such a
benefit of CGP in patients with CUP, compared with tradi-
tional chemotherapy, has yet to be reported. In 2017, a pro-
spective clinical trial evaluating the clinical benefit of high-
throughput genomic analysis in patients with advanced and
heavily pretreated cancers found approximately one-third
of patients had improved outcomes with molecularly
guided therapy [41]. However, randomized controlled trials
are required to quantify the impact of such an approach in
the general population of patients with metastatic cancers,
especially in cases without extensive pretreatment. A large
meta-analysis of phase II single-agent clinical trials revealed
that a personalized strategy matching genomic alterations
with available targeted therapies was an independent pre-
dictor of improved response rate, disease-free survival, and
OS and fewer treatment-related deaths when compared
with unmatched chemotherapy regimens in a wide array of
tumor types [42]. Additionally, various clinical trials
assessing the impact of mutation-specific inhibitors, includ-
ing those targeting BRAF, ERBB2, BRCA1/2, RET, or NTRK
alterations, have shown efficacy in many cancers other than
CUP, including lung carcinomas, colorectal cancers, papillary
thyroid cancers, and other solid tumors [43–47].
Importantly, in contrast to a mutation-matched therapy
approach, a recent phase II trial and the phase II GEFCAPI
04 trial of patients with CUP assessed the efficacy of site-
specific chemotherapy directed by gene expression profiling
to determine the tissue of origin, versus nonspecific
platinum-based chemotherapy; no significant improvement
in 1-year survival rate, OS, or PFS was demonstrated [7, 8].
Gene expression-based tissue of origin determination in iso-
lation therefore failed as a strategy to improve the progno-
sis of patients with unfavorable CUP, further emphasizing
the need for novel, primary site-independent treatment
options. These negative data support the premise of
CUPISCO, which, in contrast to tissue of origin-based con-
ventional chemotherapy, will investigate efficacy of CGP-
informed targeted therapy irrespective of the primary tis-
sue site [10]. In addition, a clinical tumor board based on a
central pathology review with an expanded
immunohistological marker panel will ensure that only CUP
cases with unfavorable outcome are included in CUPISCO.
The study presented here was a successful proof of concept
for CUPISCO and identified additional biomarkers that may
be a target for treatment in patients with CUP. It should be
noted that, despite the negative data regarding site-specific
treatment based on origin determination by gene expres-
sion in patients with CUP, ongoing CUP trials still require
identification of a primary tumor origin to avoid including
patients without CUP. CGP used here may therefore help to
identify these primary tumor origins and thus improve trial
enrollment.
CONCLUSIONS
The results of the present study showed that approximately
32% of patients with studied CUP specimens would have
been eligible for molecularly guided therapy in CUPISCO,
thus validating the experimental arms included in the study.
Genomic profiling also suggested that additional bio-
markers, such as PD-L1 positivity and gLOH, may be useful
in future studies to identify a greater proportion of patients
with CUP potentially benefiting from CGP-informed treat-
ment. These results provide much needed insight into the
therapeutic application of CGP, an approach that will hope-
fully help to improve the poor prognosis of patients
with CUP.
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Table 1. Genomic alterations and corresponding treatment options in 303 patients with CUP
CUPISCO arm Genomic alterations (%)
Any targeted therapy 31.7
Subcutaneous trastuzumab + intravenous pertuzumab + intravenous chemotherapy
(ERBB2 actionable alterations)
9.0
Atezolizumab (TMB-high [≥16 mutations/Mb], MSI-high) 9.0
Ipatasertib plus paclitaxel (AKT1, PI3K actionable alterations, PTEN loss) 8.0
Olaparib (BRCA1, BRCA2 or select alterations in BRIP1/PALB2) 6.0
Vemurafenib + cobimetinib (BRAFV600 alterations) 3.0
Erlotinib + bevacizumab (EGFR actionable alterations) 2.0
Vismodegib (inactivating PTCH1, activating SMO alterations) 1.0
Alectinib (ALK, RET rearrangements) 1.0
Entrectinib 0.33
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Figure 1. CUPISCO study design. aBased on eligibility criteria that are summarized at ClinicalTrials.gov: NCT03498521 [46]. Randomi-
zation is stratified by gender and response during the induction period (CR + PR vs. SD).
Abbreviations: CGP, comprehensive genomic profiling; CR, complete response; CUP, carcinoma-of-unknown-primary-origin; EOI,
end of induction; EOT, end of treatment; MGT, molecularly guided therapy; MTB, molecular tumor board; PD, progressive disease;
PR, partial response; PT, pretreatment; R, randomization; SD, stable disease.
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Figure 2. Sample, analysis, and report flow. (A): FFPE tumor sample. (A): Sequencing library preparation. (C): Analysis pipeline. (D):
Clinical report.
Abbreviation: FFPE, formalin-fixed, paraffin-embedded.
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Figure 3. Long tail plot of genomic alterations in 303 cases of carcinoma of unknown primary origin. Genes shown have an alter-
ation frequency of 1% or higher.
Abbreviations: CN, copy number alteration; RE, rearrangement; SV, short variant.
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Figure 4. Long tail plot of genomic alterations in tumor mutational burden (TMB)-high and TMB-low cases. Genes shown have an
alteration frequency of 1% or higher. For each gene, the alteration frequency for TMB-high and TMB-low cases is indicated by the
left and right bar, respectively.
Abbreviations: CN, copy number alteration; RE, rearrangement; SV, short variant.
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Figure 5. Tile plot of overlap of biomarkers gLOH-high, TMB-high, PD-L1-high, and MSI-high.
Abbreviations: gLOH, genomic loss of heterozygosity; MSI, microsatellite instability; MSS, microsatellite stable; Mut, mutation; PD-
L1, programmed death-ligand 1; TMB, tumor mutational burden.
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